CTI closes in on spinoff plans
In March, Cell Therapeutics said it hoped to spin off parts of the company's Systems Medicine subsidiary and its operations in Bresso, Italy, in order to create a new company that would allow drug...
View ArticleCellCyte Genetics may shut down
CellCyte Genetics, the Bothell stem cell company, says it does not have enough cash to fund its operations beyond the next month and has stopped paying its employees.
View ArticlePATH to fund vaccine research at biotech
PATH, the Seattle-based global health non-profit, said today it would fund preclinical research at a Missoula, Mont., biotech, which is developing vaccine candidates against Shigella bacteria that can...
View ArticleSonus shareholders approve merger
Sonus Pharmaceuticals said today that its shareholders had overwhelmingly approved the company's merger with Vancouver, B.C.-based OncoGenex Technologies.
View ArticleAnother Seattle biotech faces delisting
Oncothyreon said Wednesday it had received a notice from the Nasdaq Stock Market saying that it was not in compliance with a requirement that its market value be at least $50 million.
View ArticleOncoGenex lays off 21 employees here
I updated this post with information from an interview with OncoGenex's CEO
View ArticleMid-day round-up: OncoGenex, Amgen
Amgen said this morning that Nplate, its treatment for Idiopathic thrombocytopenic purpura, a rare bleeding disorder, has been approved by the FDA. Read a release here. The approval was expected,...
View ArticleStories to watch: The comeback companies
Second in a series on the blog looking at stories to watch during the coming months
View ArticleStories to watch: Amgen’s Elliott Bay plans
Third in a series on the blog looking at stories to watch during the coming months
View ArticleStories to watch: Provenge
Fourth in a series on the blog looking at stories to watch during the coming months
View ArticleRound-up: Dendreon, SonoSite
A day after rival Cell Genesys halted a trial of its prostate cancer drug due to safety questions, Dendreon's stock actually inched up 1.4 percent. Some reports appeared to suggest that Cell Genesys'...
View ArticleStories to watch: ZGEN and SGEN
[Note: My time at the Seattle Post-Intelligencer is up, so this blog is no longer being updated. Please e-mail margaretsantjer@seattlepi.com with any life sciences related story ideas or news]
View Article
More Pages to Explore .....